Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Post by AmorFatiforlifeon Feb 23, 2021 1:23am
216 Views
Post# 32634150

Q1 Financials

Q1 FinancialsI believe our Q1 was announced around the end of March last year.. We should be gearing up pretty soon for Q1 2021. I'm wondering if we will get some further funding from Baxter this go around? If memory serves Tigris was supposed to be wrapping up OCT 2021... I'm sure with cv19 there will be some grace given, unless of course the efficacy of the data supports what was already proven in the Euphrates Trial and we can finally get the proverbial show on the road. I've become accustomed to management keeping overtly tight lipped about their future plans, however it seems that we should get some news shortly as to their plan to roll out Dialco and/or list on a major US exchange. My only issue with the US listing is that it doesn't really play into the buyout theory... If a deal has already been shook upon i don't see them jumping through all those hoops to get US exposure to.drive share price if they haven't done anything in the last four + years to get this story out there. In the famous words of William Blake "What is now proved, was once imagined" i think this ties in nicely with our little diamond in the rough... Regards.
<< Previous
Bullboard Posts
Next >>